Bio-Rad Reports Third-Quarter 2023 Financial Results

Rhea-AI Summary

Bio-Rad Laboratories, Inc. reports financial results for Q3 2023. Total net sales decreased by 7.1% compared to the same period last year. Life Science segment net sales decreased by 17.1%, while Clinical Diagnostics segment net sales increased by 1.7%. Gross margin was 53.1%. Net income for Q3 2023 was $106.3 million compared to a net loss of $162.8 million in Q3 2022.

Positive

• Total net sales for Q3 2023 decreased by 7.1% compared to the same period last year.
• Clinical Diagnostics segment net sales increased by 1.7% in Q3 2023.
• Net income for Q3 2023 was $106.3 million compared to a net loss of $162.8 million in Q3 2022.

Negative

• Life Science segment net sales decreased by 17.1% in Q3 2023.
• Gross margin decreased to 53.1% in Q3 2023.

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.

Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the third quarter of 2023 versus approximately $17.2 million in the year ago period. Excluding COVID-related sales, revenue decreased 5.5 percent on a currency-neutral basis.

Life Science segment net sales for the third quarter were $263.5 million, a decrease of 17.1 percent compared to the same period in 2022. On a currency-neutral basis, Life Science segment sales decreased by 17.8 percent compared to the same quarter in 2022. Excluding COVID-related sales, Life Science revenue decreased 13.7 percent and was primarily driven by lower sales of qPCR and process chromatography, and western blotting products.

Clinical Diagnostics segment net sales for the third quarter were $368.1 million, an increase of 1.7 percent compared to the same period in 2022. On a currency-neutral basis, net sales increased 1.0 percent versus the same quarter last year. Excluding COVID-related sales, Clinical Diagnostics revenue increased 1.4 percent year over year, on a currency-neutral basis, driven by increased demand for diagnostic testing systems, as well as quality control products.

Third-quarter gross margin was 53.1 percent compared to 54.7 percent during the third quarter of 2022.

Income from operations during the third quarter of 2023 was $90.9 million versus $94.6 million during the same quarter last year.

Net income for the third quarter of 2023 was $106.3 million, or $3.64 per share, on a diluted basis, versus a net loss of $162.8 million, or $5.48 per share, on a diluted basis, during the same period in 2022. Net income and net loss amounts for the third quarter of 2023 and 2022 were primarily impacted by the recognition of changes in the fair market value of equity securities related to the holdings of the company’s investment in Sartorius AG.

The effective tax rate for the third quarter of 2023 was 22.5 percent, compared to 21.5 percent for the same period in 2022. The third quarter 2023 effective tax rate was primarily affected by an unrealized gain in equity securities and the tax rate reported in the third quarter of 2022 was primarily affected by an unrealized loss in equity securities.

“Our third-quarter results came in below our expectations and were primarily impacted by further deterioration in biopharma and early biotech customer spending, as well as a challenging macroeconomic environment in China,” said Norman Schwartz, Bio-Rad’s President and Chief Executive Officer. “Given the uncertain pace of the biopharma sector’s recovery and the ongoing macro challenges, we are lowering our full-year 2023 outlook but remain confident about our overall strategy framework and long-term market opportunities.”

The non-GAAP financial measures discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP and Currency-Neutral Reporting.” A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Non-GAAP gross margin was 53.9 percent for the third quarter of 2023 compared to 55.6 percent during the third quarter of 2022.

Non-GAAP income from operations during the third quarter of 2023 was $81.6 million versus $107.6 million during the comparable prior-year period.

Non-GAAP net income for the third quarter of 2023 was $68.1 million, or $2.33 per share, on a diluted basis, compared to $79.2 million, or $2.64 per share, on a diluted basis, during the same period in 2022.

The non-GAAP effective tax rate for the third quarter of 2023 was 23.9 percent, compared to 21.7 percent for the same period in 2022. The higher rate in 2023 was driven by geographical mix of earnings and reduced compensation-related deductions.

GAAP Results
	Q3 2023	Q3 2022
Revenue (millions)	$632.1	$680.8
Gross margin	53.1%	54.7%
Operating margin	14.4%	13.9%
Net income (loss) (millions)	$106.3	($162.8)
Income (loss) per diluted share	$3.64	($5.48)
Non-GAAP Results
	Q3 2023	Q3 2022
Revenue (millions)	$632.1	$680.8
Gross margin	53.9%	55.6%
Operating margin	12.9%	15.8%
Net income (millions)	$68.1	$79.2
Income per diluted share	$2.33	$2.64

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

Updated 2023 Financial Outlook

Bio-Rad is updating its financial outlook for full-year 2023. The company currently expects its non-GAAP revenue to decline by approximately 3.5 percent on a currency-neutral basis compared to its previous estimate of a 0.8 percent revenue growth. Bio-Rad also estimates a non-GAAP operating margin of about 14.5 percent versus the company’s prior estimate of approximately 16 percent. Excluding COVID-related sales, Bio-Rad estimates non-GAAP revenue growth to be between 0 and 0.5 percent on a currency-neutral basis compared to its prior expectation of approximately 4.5 percent.

Conference Call and Webcast

Management will discuss the company’s third quarter 2023 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on October 26, 2023. To participate, dial 888-259-6580 within the U.S., or (+1) 206-962-3782 from outside the U.S., and provide access code: 65942913.

A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

Use of Non-GAAP and Currency-Neutral Reporting

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, gains and losses from change in fair market value of equity securities and loan receivable, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

Restructuring, impairment charges, and gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses (including impairments) on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; remaining confident about our overall strategy framework and long-term market opportunities; and for the full-year 2023: currently expecting non-GAAP revenue to decline by approximately 3.5 percent on a currency-neutral basis, estimating a non-GAAP operating margin of about 14.5 percent, and excluding COVID-related sales, estimating non-GAAP revenue growth to be between 0 and 0.5 percent on a currency-neutral basis. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect,” "estimate," "anticipate," “target,” "continue," "believe," "will," "project," "assume," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include reductions in government funding or capital spending of our customers, global economic and geopolitical conditions, the uncertain pace of the biopharma sector’s recovery, the challenging macroeconomic environment in China, the impact of the COVID-19 pandemic, supply chain issues, international legal and regulatory risks, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income (Loss)
(In thousands, except per share data)
(Unaudited)
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2023				2022				2023				2022
Net sales			$	632,124			$	680,800			$	1,990,078			$	2,071,961
	Cost of goods sold			296,441				308,233				929,495				901,728
Gross profit				335,683				372,567				1,060,583				1,170,233
	Selling, general and administrative expense			201,199				211,113				634,576				615,598
	Research and development expense			43,535				66,808				183,528				190,689
Income from operations				90,949				94,646				242,479				363,946
	Interest expense			12,398				11,663				37,078				26,431
	Foreign currency exchange (gains) losses, net			(1,680	)			4,364				(5,280	)			3,133
	(Gains) losses from change in fair market value of equity securities and loan receivable			(36,425	)			288,999				1,576,542				6,172,306
	Other income, net			(20,446	)			(3,062	)			(87,365	)			(42,369	)
Income (loss) before income taxes				137,102				(207,318	)			(1,278,496	)			(5,795,555	)
	(Provision for) benefit from income taxes			(30,845	)			44,510				291,464				1,340,286
Net income (loss)			$	106,257			$	(162,808	)		$	(987,032	)		$	(4,455,269	)
Basic earnings (loss) per share:
	Net income (loss) per basic share		$	3.65			$	(5.48	)		$	(33.63	)		$	(149.41	)
	Weighted average common shares - basic			29,102				29,733				29,349				29,819
Diluted earnings (loss) per share:
	Net income (loss) per diluted share		$	3.64			$	(5.48	)		$	(33.63	)		$	(149.41	)
	Weighted average common shares - diluted			29,223				29,733				29,349				29,819
	Note: As a result of the net loss for the three months ended September 30, 2022 and the nine months ended September 30, 2023 and 2022,
	all potentially issuable common shares have been excluded from the diluted shares
	used in the computation of earnings per share as their effect was anti-dilutive.

Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
			September 30,			December 31,
			2023			2022
			(Unaudited)
Current assets:
	Cash and cash equivalents		$	457,850		$	434,215
	Short-term investments			1,306,703			1,362,017
	Accounts receivable, net			457,402			494,645
	Inventories, net			775,818			719,316
	Other current assets			148,997			147,783
	Total current assets			3,146,770			3,157,976
Property, plant and equipment, net				511,389			498,612
Operating lease right-of-use assets				200,013			180,952
Goodwill, net				406,953			406,488
Purchased intangibles, net				314,187			332,147
Other investments				7,218,161			8,830,892
Other assets				98,470			94,599
		Total assets	$	11,895,943		$	13,501,666
Current liabilities:
	Accounts payable, accrued payroll and employee benefits		$	266,805		$	329,831
	Current maturities of long-term debt			476			465
	Income and other taxes payable			103,978			32,428
	Other current liabilities			186,917			205,984
	Total current liabilities			558,176			568,708
Long-term debt, net of current maturities				1,198,713			1,197,716
Other long-term liabilities				1,722,856			2,119,990
		Total liabilities		3,479,745			3,886,414
		Total stockholders' equity		8,416,198			9,615,252
		Total liabilities and stockholders' equity	$	11,895,943		$	13,501,666

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
				Nine Months Ended
				September 30,
				2023				2022
Cash flows from operating activities:
	Cash received from customers			$	2,007,482			$	1,981,952
	Cash paid to suppliers and employees				(1,722,173	)			(1,800,487	)
	Interest paid, net				(46,394	)			(23,974	)
	Income tax payments, net				(40,966	)			(137,863	)
	Other operating activities				95,947				95,162
	Net cash provided by operating activities				293,896				114,790
Cash flows from investing activities:
	Payments for acquisitions				-				(100,746	)
	Payments for purchases of marketable securities and investments				(537,540	)			(1,807,148	)
	Proceeds from sales and maturities of marketable securities and investments				599,882				835,366
	Other investing activities				(114,331	)			(76,513	)
	Net cash used in investing activities				(51,989	)			(1,149,041	)
Cash flows from financing activities:
	Proceeds from issuance of Notes, net of debt financing costs				-				1,186,220
	Payments on long-term borrowings				(349	)			(367	)
	Other financing activities				(224,678	)			(125,658	)
	Net cash provided by (used in) financing activities				(225,027	)			1,060,195
Effect of foreign exchange rate changes on cash					6,891				21,167
Net increase in cash, cash equivalents and restricted cash					23,771				47,111
Cash, cash equivalents and restricted cash at beginning of period					434,544				471,133
Cash, cash equivalents and restricted cash at end of period				$	458,315			$	518,244
Reconciliation of net loss to net cash
provided by operating activities:
Net loss				$	(987,032	)		$	(4,455,269	)
Adjustments to reconcile net loss to net cash
provided by operating activities:
	Depreciation and amortization				108,724				101,782
	Reduction in the carrying amount of right-of-use assets				30,725				29,828
	Losses from change in fair market value of equity securities and loan receivable				1,576,542				6,172,306
	Changes in working capital				(61,623	)			(343,972	)
	Other				(373,440	)			(1,389,885	)
Net cash provided by operating activities				$	293,896			$	114,790

Bio-Rad Laboratories, Inc.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In thousands, except per share data)
(Unaudited)
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.
			Three Months Ended							Three Months Ended							Nine Months Ended							Nine Months Ended
			September 30,				% of			September 30,				% of			September 30,				% of			September 30,				% of
			2023				revenue			2022				revenue			2023				revenue			2022				revenue
GAAP cost of goods sold			$	296,441						$	308,233						$	929,495						$	901,728
	Amortization of purchased intangibles			(4,507	)						(4,430	)						(13,131	)						(13,341	)
	Restructuring benefits (costs)			(215	)						(1,285	)						(3,922	)						(1,288	)
Non-GAAP cost of goods sold			$	291,719						$	302,518						$	912,442						$	887,099
GAAP gross profit			$	335,683			53.1	%		$	372,567			54.7	%		$	1,060,583			53.3	%		$	1,170,233			56.5	%
	Amortization of purchased intangibles			4,507							4,430							13,131							13,341
	Restructuring (benefits) costs			215							1,285							3,922							1,288
Non-GAAP gross profit			$	340,405			53.9	%		$	378,282			55.6	%		$	1,077,636			54.2	%		$	1,184,862			57.2	%
GAAP selling, general and administrative expense			$	201,199						$	211,113						$	634,576						$	615,598
	Amortization of purchased intangibles			(1,629	)						(1,804	)						(4,931	)						(5,494	)
	Legal matters			-							2							-							(2,066	)
	Acquisition related benefits (costs)			4,100							-							4,100							-
	Restructuring benefits (costs)			(1,339	)						(2,782	)						(16,655	)						(2,945	)
	Other non-recurring items (2)			(1,877	)						(2,176	)						(5,794	)						(7,506	)
Non-GAAP selling, general and administrative expense			$	200,454						$	204,353						$	611,296						$	597,587
GAAP research and development expense			$	43,535						$	66,808						$	183,528						$	190,689
	Acquisition related benefits (costs)			14,800							-							14,400							-
	Restructuring benefits (costs)			22							(495	)						(5,293	)						(330	)
Non-GAAP research and development expense			$	58,357						$	66,313						$	192,635						$	190,359
GAAP income from operations			$	90,949			14.4	%		$	94,646			13.9	%		$	242,479			12.2	%		$	363,946			17.6	%
	Amortization of purchased intangibles			6,136							6,234							18,062							18,835
	Legal matters			-							(2	)						-							2,066
	Acquisition related (benefits) costs			(18,900	)						-							(18,500	)						-
	Restructuring (benefits) costs			1,532							4,562							25,870							4,563
	Other non-recurring items (2)			1,877							2,176							5,794							7,506
Non-GAAP income from operations			$	81,594			12.9	%		$	107,616			15.8	%		$	273,705			13.8	%		$	396,916			19.2	%
GAAP (gains) losses from change in fair market value of equity securities and loan receivable			$	(36,425	)					$	288,999						$	1,576,542						$	6,172,306
	Gains (losses) from change in fair market value of equity securities and loan receivable			36,425							(288,999	)						(1,576,542	)						(6,172,306	)
Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable			$	-						$	-						$	-						$	-
GAAP other (income) expense, net			$	(20,446	)					$	(3,062	)					$	(87,365	)					$	(42,369	)
	Gains (losses) on equity-method investments			(697	)						(6,554	)						(2,543	)						(9,177	)
	Other non-recurring items (3)			2,500							-							2,500							1,360
Non-GAAP other (income) expense, net			$	(18,643	)					$	(9,616	)					$	(87,408	)					$	(50,186	)
GAAP income (loss) before income taxes			$	137,102						$	(207,318	)					$	(1,278,496	)					$	(5,795,555	)
	Amortization of purchased intangibles			6,136							6,234							18,062							18,835
	Legal matters			-							(2	)						-							2,066
	Acquisition related (benefits) costs			(18,900	)						-							(18,500	)						-
	Restructuring (benefits) costs			1,532							4,562							25,870							4,563
	(Gains) losses from change in fair market value of equity securities and loan receivable			(36,425	)						288,999							1,576,542							6,172,306
	(Gains) losses on equity-method investments			697							6,554							2,543							9,177
	Other non-recurring items (2) (3)			(623	)						2,176							3,294							6,146
Non-GAAP income before income taxes			$	89,519						$	101,205						$	329,315						$	417,538
GAAP (provision for) benefit from income taxes			$	(30,845	)					$	44,510						$	291,464						$	1,340,286
	Income tax effect of non-GAAP adjustments (1)			9,408							(66,495	)						(364,826	)						(1,423,735	)
Non-GAAP provision for income taxes			$	(21,437	)					$	(21,985	)					$	(73,362	)					$	(83,449	)
GAAP net income (loss)			$	106,257			16.8	%		$	(162,808	)		-23.9	%		$	(987,032	)		-49.6	%		$	(4,455,269	)		-215.0	%
	Amortization of purchased intangibles			6,136							6,234							18,062							18,835
	Legal matters			-							(2	)						-							2,066
	Acquisition related (benefits) costs			(18,900	)						-							(18,500	)						-
	Restructuring (benefits) costs			1,532							4,562							25,870							4,563
	(Gains) losses from change in fair market value of equity securities and loan receivable			(36,425	)						288,999							1,576,542							6,172,306
	(Gains) losses on equity-method investments			697							6,554							2,543							9,177
	Other non-recurring items (2) (3)			(623	)						2,176							3,294							6,146
	Income tax effect of non-GAAP adjustments (1)			9,408							(66,495	)						(364,826	)						(1,423,735	)
Non-GAAP net income			$	68,082			10.8	%		$	79,220			11.6	%		$	255,953			12.9	%		$	334,089			16.1	%
GAAP diluted income (loss) per share			$	3.64						$	(5.48	)					$	(33.63	)					$	(149.41	)
	Amortization of purchased intangibles			0.21							0.21							0.61							0.63
	Legal matters			-							-							-							0.07
	Acquisition related (benefits) costs			(0.65	)						-							(0.63	)						-
	Restructuring (benefits) costs			0.05							0.15							0.88							0.15
	(Gains) losses from change in fair market value of equity securities and loan receivable			(1.25	)						9.65							53.47							205.35
	(Gains) losses on equity-method investments			0.02							0.22							0.09							0.31
	Other non-recurring items (2) (3)			(0.02	)						0.07							0.11							0.20
	Income tax effect of non-GAAP adjustments (1)			0.33							(2.22	)						(12.38	)						(47.36	)
	Add back anti-dilutive shares			-							0.04							0.16							1.18
Non-GAAP diluted income per share			$	2.33						$	2.64						$	8.68						$	11.12
GAAP diluted weighted average shares used in per share calculation				29,223							29,733							29,349							29,819
	Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive			-							218							137							238
Non-GAAP diluted weighted average shares used in per share calculation				29,223							29,951							29,486							30,057
Reconciliation of Net income (loss) to adjusted EBITDA:
GAAP net income (loss)			$	106,257			16.8	%		$	(162,808	)		-23.9	%		$	(987,032	)		-49.6	%		$	(4,455,269	)		-215.0	%
	Interest expense			12,398							11,663							37,078							26,431
	(Provision for) benefit from income taxes			30,845							(44,510	)						(291,464	)						(1,340,286	)
	Depreciation and amortization			37,278							34,269							108,724							101,782
	Foreign currency exchange (gains) losses, net			(1,680	)						4,364							(5,280	)						3,133
	Other income, net			(20,446	)						(3,062	)						(87,365	)						(42,369	)
	(Gains) losses from change in fair market value of equity securities and loan receivable			(36,425	)						288,999							1,576,542							6,172,306
	Dividend from Sartorius AG			-							-							34,766							31,586
	Legal matters			-							(2	)						-							2,066
	Acquisition related (benefits) costs			(18,900	)						-							(18,500	)						-
	Restructuring (benefits) costs			1,532							4,562							25,870							4,563
	Other non-recurring items (2)			1,877							2,176							5,794							7,506
Adjusted EBITDA			$	112,736			17.8	%		$	135,651			19.9	%		$	399,133			20.1	%		$	511,449			24.7	%
(1) Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax
	provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.
(2) Incremental costs to comply with the European Union's In Vitro Diagnostics Regulation ("IVDR") for previously approved products.
(3) Gain from the release of an escrow for the acquisition in 2021 (2023) and for the sale of a division in 2020 (2022).
2023 Financial Outlook
Forecasted non-GAAP operating margin excludes 88 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026420974/en/

Investor Contact:

Edward Chung, Investor Relations

510-741-6104

ir@bio-rad.com

Media Contact:

Anna Gralinska, Corporate Communications

510-741-6643

cc@bio-rad.com

Source: Bio-Rad Laboratories, Inc.

FAQ

What was the change in total net sales for Q3 2023 compared to the same period last year?

Total net sales for Q3 2023 decreased by 7.1% compared to the same period last year.

How did the Clinical Diagnostics segment perform in Q3 2023?

Clinical Diagnostics segment net sales increased by 1.7% in Q3 2023.

What was the net income for Q3 2023?

Net income for Q3 2023 was $106.3 million compared to a net loss of $162.8 million in Q3 2022.